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 2 
Abstract  29 
The expression of anti-inflammatory IL-10 by CD4+ T cells is indispensable for 30 
immune homeostasis as it allows T cells to moderate their effector function. We 31 
previously showed that TNFα blockade during T cell stimulation in CD4+ T 32 
cell/monocyte co-cultures resulted in maintenance of IL-10 producing T cells and 33 
identified IKZF3 as a putative regulator of IL-10. Here, we tested the hypothesis that 34 
IKZF3 is a transcriptional regulator of IL-10 using a human CD4+ T cell only culture 35 
system. IL-10+CD4+ T cells expressed the highest levels of IKZF3 both ex vivo and 36 
after activation, compared to IL-10-CD4+ T cells. Pharmacological targeting of IKZF3 37 
with the drug lenalidomide showed that IKZF3 is required for anti-CD3/CD28 mAb-38 
mediated induction of IL-10 but is dispensable for ex vivo IL-10 expression. 39 
However, overexpression of IKZF3 was unable to upregulate IL-10 at the mRNA or 40 
protein level in CD4+ T cells and did not drive the transcription of the IL10 promoter 41 
or putative local enhancer constructs. Collectively, these data indicate that IKZF3 is 42 




Key points: 47 
Anti-TNF maintains IL10 expression in CD4+ T cells at the transcriptional level 48 
 49 
IKZF3 is enriched in IL-10+CD4+ T cells; degrading IKZF3 disrupts IL-10 production 50 
  51 
Overexpression of IKZF3 does not drive IL10 nor activate local enhancers 52 
 53 
 54 
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Introduction  56 
The production of IL-10 by CD4+ T cells is key for the control of effector function in 57 
response to immune challenge (1-3). Even in the absence of pathogens, CD4+ T cell 58 
specific deletions of Il10 lead to a pronounced inflammation in the colonic mucosa in 59 
response to commensal gut bacteria (1). 60 
IKZF3 (encoding for the protein Aiolos) is a member of the Ikaros Zinc finger family of 61 
transcription factors (4). This gene is expressed by various immune cell types and has 62 
been implicated in the function of multiple T helper subsets (5, 6) as well as in 63 
controlling CD4/CD8 fate decision in the thymus (7). The expression of IKZF3 in IL-17 64 
producing CD4+ T cells (Th17 cells) is associated with a “non-pathogenic” signature 65 
which includes increased IL-10 production (6, 8). IKZF3 has also been shown to 66 
interact with known regulators of IL10 expression including its most closely related 67 
family member IKZF1 (encoding Ikaros) (4) which has been shown in mice to directly 68 
affect the expression of Il10 (9).  69 
While IKZF3 has been suggested to act as a transcriptional activator in CD4+ T cells 70 
(4, 10), this has mainly been ascribed to its cooperation with other factors such as 71 
FOXP3 (11) and BLIMP1 in regulatory CD4+ T cells (Tregs) (12), and with STAT3 in 72 
T follicular helper cells (TFH) (13). Studies in multiple cell lines highlight the ability of 73 
IKZF3 to repress gene expression, through HDAC and PRC2 recruitment (14-16) as 74 
well as by altering chromatin superstructure (17). 75 
Anti-TNFα mAb therapy is commonly used in the treatment of many inflammatory 76 
conditions including rheumatoid arthritis (18), inflammatory bowel disease (19) and 77 
psoriasis (20). Although the mechanisms governing its therapeutic effects are still not 78 
entirely elucidated, multiple effects on the immune system have been reported 79 
including induction of an anti-inflammatory CD4+ T cell phenotype (21), modulation of 80 
innate immune cell function (22, 23), expansion of Tregs (24), in addition to blocking 81 
TNFα proinflammatory signalling. We previously demonstrated that patients with 82 
rheumatoid arthritis or ankylosing spondylitis treated with anti-TNFα drugs have 83 
increased frequencies of IL-10+ CD4+ T cells in peripheral blood (10). Furthermore, 84 
CD4+ T cells from the peripheral blood of healthy volunteers activated in the presence 85 
of anti-TNFα therapeutics, had increased frequencies of IL-10+ cells (10, 25). Gene 86 
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expression analysis from one of these studies highlighted IKZF3 as a potential 87 
regulator of IL-10 expression, at least in Th17 cells (10). 88 
Here we sought to address the hypothesis that IKZF3 is a transcriptional regulator 89 
IL-10 production in CD4+ T cells. 90 
  91 
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Materials and Methods 92 
Cells and cell culture 93 
Peripheral blood was obtained from healthy adult volunteers with written informed 94 
consent (Bromley Research Ethics Committee ref 06/Q0705/20). Peripheral blood 95 
mononuclear cells (PBMCs) were isolated using density gradient centrifugation. 96 
CD4+ T cells and CD14+ monocytes were isolated by magnetic-activated cell sorting 97 
(MACS) using the manufacturer’s protocol. CD14+ monocytes were isolated using 98 
anti-CD14+ microbeads to ~98% purity (Miltenyi Biotech), and CD4+ T cells were 99 
isolated using negative selection ~95% (Miltenyi Biotech).  100 
Cells were cultured in RPMI 1640 (Gibco) supplemented with 10% FCS and 1% 101 
penicillin, streptomycin and 10mg/mL L-glutamine (culture medium). CD4+ T cell 102 
cultures were stimulated with anti-CD3/CD28 mAb stimulation, by coating tissue 103 
culture plate wells with 1.25μg/mL α-CD3 mAb OKT3 (Janssen-Cilag Ltd) in PBS for 104 
3 hours at 37oC. Wells were washed with sterile PBS before adding the cells 105 
(106/mL) together with 1 μg/mL anti-CD28 mAb (clone CD8.2; BD Biosciences). For 106 
co-cultures, 0.5x106 CD14+ peripheral blood monocytes were cultured with 0.5x106 107 
autologous CD4+ T cells in 1ml of culture medium in the presence of 100ng/mLanti-108 
CD3mAb (OKT3). HEK293T cells (gifted from Stuart Neil lab, King’s College London, 109 
UK) were cultured in DMEM, supplemented with 10% FCS, 1% penicillin, 110 
streptomycin and 10mg/mL L-glutamine. 111 
Flow cytometry 112 
For intracellular staining, CD4+ T cells, or CD4+ T cell/monocyte co-cultures were 113 
stimulated for 3 hours in the presence of PMA (50ng/mL, Sigma Aldrich), ionomycin 114 
(750ng/mL, Sigma Aldrich) and GolgiStop (BD, as per manufacturer’s instructions). 115 
Cells were washed and stained with CD3-PE Cy7 (UCHT1, Biolegend) and 116 
Live/Dead efluor780 (Thermo Fisher). Cells were then fixed in 2% PFA and 117 
permeabilised with 0.5% Saponin (Thermo Fisher). Cells were subsequently stained 118 
for the following cytokines: IL-10-AlexaFluor488 (JES3-9D7, Biolegend), IL-17A-PE 119 
(BL168, Biolegend), IFNγ-Pacific blue (4S.B3, Biolegend) and, TNF-APC (MAb11, 120 
Biolegend). 121 
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For intranuclear staining of IKZF3, cells were fixed and permeabilised with FOXP3 122 
staining buffer (Biolegend) for 15 minutes at room temperature before being stained 123 
for CD3-PE Cy7, IL-10-Alexafluor488, IL-17A-PE, IFNγ-Pacific blue, TNF-BV605 124 
(MAb11, Biolegend) and either, IKZF3-AF647 (EPR9342(B), Abcam) or isotype 125 
control (EPR25A, Abcam) for 30 minutes. Standard gating strategy for intracellular 126 
cytokine staining is shown in supplemental figure 1A-C 127 
RNA isolation and qPCR 128 
mRNA was isolated using RNEASY mini kit (Qiagen). cDNA was transcribed using a 129 
High Capacity cDNA RT Kit (Applied Biosystems) according to the manufacturer’s 130 
protocol. Realtime PCR was performed using SensiFAST SYBR Green PCR master 131 
mix (Bioline) with 10uM of primers (Table 1). Reactions were performed in multiple 132 
technical replicates and results calculated using the dCT method.  133 
Actinomycin D assay 134 
CD4+ T cells stimulated with anti-CD3/CD28 mAb cultured in the presence or 135 
absence of 1 μg/mL adalimumab for 72 hours. After stimulation the cells were 136 
treated for 2 hours with either 1 μg/mL Actinomycin D (Cambridge Biosciences) or 137 
equivalent volume of DMSO. Cells were subsequently harvested for RNA and 138 
assayed for gene expression by qPCR. 139 
Viral transduction of CD4+ T cells 140 
The plasmids pCSIG-IKZF3-GFP (lenti-IKZF3) and pCSIG-GFP (lenti-EV) were 141 
packaged into lentiviral particles by transfecting HEK293T cells with a pCSIG vector, 142 
pSPAX2 and pMD2.G. Viral particles were concentrated using PEG-IT (Cambridge 143 
Bio) according to manufacturer’s instructions. 144 
Primary CD4+ T cells were activated with platebound anti-CD3 and anti-CD28 mAb 145 
(2 μg/mL) with 20 U/mL rhIL-2 (Peprotech) for 24 hours at a density of 106 cells/mL. 146 
Viral supernatants were mixed with TRANSDUX MAX (Cambridge Bioscience), 147 
added to the cells and cultured. After 3 days, the cells were supplemented with fresh 148 
10% FCS RPMI and 20 U/mL of rhIL-2 and rested from stimulation for 3 days. These 149 
cells were subsequently sorted on live CD3+ GFP+/- cells (Supplemental Figure 1D). 150 
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Cells were sorted and rested overnight at a density of 105 cells/mL then stained for 151 
IL-10, IL-17A, IFNγ and IKZF3. 152 
Plasmids and cloning 153 
The selected regions of the human IL10 locus (indicated in Table 2) were amplified 154 
by PCR using the BAC RP11-262N9 (Thermo Fisher) as a template, and TOPO 155 
cloned into TOPO Blunt II (Invitrogen). These were then sequenced to confirm 100% 156 
conformity to the reference sequence. These regions of interest were subcloned into 157 
a pGL4.26 vector (Promega).  158 
FLAG-cMAF-pCMV was a gift from Paul Lavender (King’s College London, UK). and 159 
HA-IKZF3 was PCR cloned from a pCMV sport vector purchased from Source 160 
BioScience.  161 
Luciferase assay 162 
HEK293T cells were seeded at a density of 200,000 cells/mL in 96 well plates. The 163 
next day, each well was transfected with 1 μg of PEI (Sigma Aldrich) mixed with 0.2 164 
μg of experimental pGL4.26, 0.01 μg of control pRL4 and 0.2 μg of transcription 165 
factor-pCSIG or empty vector. After 18 hours of transfection, the cell culture media 166 
was replaced and left for a further 48 hours before harvesting the cells. 167 
Luciferase assays were performed using the Dual-glo luciferase kit (Promega) 168 
according to manufacturer’s instructions and data collected on a Tecan Spark 10M. 169 
Firefly luciferase activity was normalised to Renilla luciferase activity for each sample 170 
to control for transfection efficiency, and further normalised to the empty vector 171 
control. 172 
Statistical analysis 173 
Statistical analysis was performed using Graphpad Prism version 8. Wilcoxon test 174 
was used for comparisons between 2 groups unless otherwise stated. Significant p 175 
values are reported as p<0.05 *, p<0.01 **, p<0.001 ***, p<0.0001 ****.  176 
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RESULTS 177 
TNFα blockade maintains IL10 transcription in CD4+ T cells 178 
We previously observed a transient increase in the frequency of IL-10+ CD4+ T cells 179 
when PBMC were stimulated with anti-CD3 mAb, which was maintained in the 180 
presence of TNFα blockade (10, 25). Since we aimed to utilise a reductionist CD4+ T 181 
cell culture in our experiments, we first sought to determine the kinetics of IL-10 182 
expression in cultures of anti-CD3/CD28 mAb stimulated CD4+ T cells rather than 183 
PBMC cultures. CD4+ T cells were purified and stimulated with platebound anti-CD3 184 
and soluble anti-CD28 mAb for 1-3 days, with or without the anti-TNFα antibody 185 
adalimumab (ADA), before being restimulated with PMA and ionomycin for 186 
intracellular cytokine staining (representative gating strategies are shown in 187 
Supplemental Figure 1). We observed a transient increase in the frequency of IL-10+ 188 
cells when CD4+ T cells were stimulated with anti-CD3/CD28 mAb, which was 189 
maintained by TNFα blockade (Figure 1A, B). To rule out a possible artefact due to 190 
the PMA/ionomycin restimulation, we examined the expression of IL10 mRNA levels 191 
by qPCR in CD4+ T cells stimulated with anti-CD3/CD28 mAb with or without anti-192 
TNF. We observed a similar pattern, namely a transient increase of IL10 expression 193 
upon stimulation, which was maintained in the presence of ADA at day 3 (Figure 1C). 194 
We also observed IL-10 secretion in the cell culture supernatant upon 3 days of anti-195 
CD3/CD28 mAb stimulation which was significantly increased in the presence of anti-196 
TNFα (Figure 1D). 197 
IL10 mRNA has been shown previously to be controlled at the post transcriptional level 198 
(26). In order to determine whether IL10 mRNA was stabilised by TNFα blockade, we 199 
performed an Actinomycin D assay on CD4+ T cells stimulated with anti-CD3/CD28 200 
mAb for 3 days. This assay is frequently used to determine the relative stability of 201 
mRNA species between treatments or cell types (27). The treatment of cells with 202 
actinomycin D inhibits mRNA transcription. Once blocked, unstable mRNA transcripts 203 
are degraded by cellular machinery over time and not replenished. Comparing mRNA 204 
levels between actinomycin D and vehicle control treated cells, gives an indication of 205 
mRNA stability. IL10 mRNA in activated CD4+ T cells was sensitive to the addition of 206 
Actinomycin D and therefore unstable, similar to MYC and unlike the more stable 207 
mRNA IL2RA (Figure 1E). We did not observe a significant difference between control 208 
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and ADA-treated CD4+ T cells. These results indicate that the increase in IL10 mRNA 209 
is due to active transcription. 210 
 211 
IKZF3 is enriched in IL-10 producing CD4+ T cells  212 
Our previous gene expression analysis indicated that IKZF3 was upregulated in Th17 213 
cells in response to TNFα blockade and could bind at the IL10 locus in these cells 214 
(10). To examine whether IKZF3 was associated with IL-10 production in CD4+ T cells, 215 
we performed a combined intracellular cytokine staining and an intranuclear stain for 216 
IKZF3 to determine the expression of IKZF3 within CD4+ T cells expressing IL-10, IL-217 
17A, IFNγ or TNFα either ex vivo or after 3 days of anti-CD3/CD28 mAb stimulation. 218 
IKZF3 was expressed at higher levels in IL-10+ CD4+ T cells compared to the total 219 
CD4+ T cell population and the IL-17A+ and TNFα+ subsets ex vivo (Figure 2A, B). 220 
Upon anti-CD3/CD28 mAb stimulation, a significant increase was observed in IKZF3 221 
expression in IL-10-expressing cells compared to the total CD4+ and the TNFα+ cell 222 
populations. However, there was no longer a significant difference between IL-10+ 223 
and IL-17A+ CD4+ T cells (Figure 2C, D). Since IL-10 can be expressed by multiple 224 
cytokine producing CD4+ T cell subsets (especially after stimulation), we compared 225 
IKZF3 expression in the IL-17A+, TNFα+ and IFNγ+ cells that co-produced IL-10 and 226 
those that did not (Figure 2E, F). In all subsets analysed, a significantly higher 227 
expression of IKZF3 was observed in IL-10 co-producing CD4+ T cells compared to 228 
cells that did not produce IL-10 (Figure 2F). 229 
In our previous work, we observed an increase in IKZF3 expression in Th17 cells 230 
following TNFα blockade using a CD14+ monocyte/CD4+ T cell co-culture system. In 231 
order to determine if the increase in IKZF3 upon TNFα blockade occurred in the 232 
absence of monocytes and in all T cell subsets,  we compared IKZF3 expression in 233 
CD4+ T cells cultured alone versus CD4+ T cells co-cultured with  CD14+ monocytes 234 
in the absence or presence of ADA (Supplemental Figure 2). We previously 235 
established that IL-10 expression is increased upon TNF blockade in both culture 236 
systems (10, 25). In agreement with our previous results, upon T cell stimulation in the 237 
presence of CD14+ monocytes and anti-TNF, IKZF3 expression was increased in the 238 
total CD4+ T cell population, as well as in the IL-10+ and IL-17A+ subsets 239 
(Supplemental Figure 2A). In the absence of CD14+ monocytes, IL-10+ CD4+ T cells 240 
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had high expression of IKZF3 in both control and ADA treated samples, but TNFα 241 
blockade did not alter IKZF3 expression in these cells (Supplemental Figure 2B, C). 242 
These data indicate that in CD4+ T cell only cultures, the anti-TNFα mediated increase 243 
of IL-10 can occur in the absence of a concomitant increase in IKZF3 expression. 244 
 245 
IKZF3 degradation by lenalidomide does not alter IL-10 expression ex vivo but 246 
disrupts anti-CD3/CD28 mAb-mediated IL-10 production 247 
We sought to determine whether IKZF3 is required for IL-10 expression. We first 248 
attempted to deplete IKZF3 from CD4+ T cells using siRNA in primary CD4+ T cells. 249 
However, this approach did not work due to the stability of the IKZF3 protein (as shown 250 
by cycloheximide assays, data not shown) and its upregulation upon anti-CD3/CD28 251 
stimulation (required to render the cells transfectable or transducable, data not 252 
shown). As an alternative approach, we employed the thalidomide derivative 253 
lenalidomide (Lena), which has been shown to induce the proteasomal degradation of 254 
IKZF3 (and IKZF1) and is used therapeutically in treating multiple myeloma (28-30).  255 
Treatment of CD4+ T cells with lenalidomide overnight led to a dose-dependent 256 
decrease in IKZF3 protein levels as shown by Western blot (Figure 3A) and flow 257 
cytometry (Figure 3B). CD4+ T cells were then treated with lenalidomide for 24 hours, 258 
in the absence of T cell activation, followed by intracellular cytokine staining. Whilst a 259 
significant reduction in the levels of IKZF3 was observed, the frequency of IL-10+ cells 260 
within CD4+ T cells was slightly increased (Figure 3C). Ex vivo treatment of CD4+ T 261 
cells with lenalidomide had no effect on IL-17A, IFNg expression or viability 262 
(Supplemental Figure 3A). In contrast, when CD4+ T cells were treated with 263 
lenalidomide for 3 days in the presence of anti-CD3/CD28 mAb stimulation, a strong 264 
reduction in both IKZF3 expression and the frequency of IL-10+ CD4+ T cells was 265 
observed (Figure 3D). These data indicate that while IL-10 production in unstimulated 266 
CD4+ T cells is not lenalidomide-sensitive, the anti-CD3/CD28-mAb mediated 267 
increase in IL-10 expressing cells is lenalidomide-sensitive, and thus by extrapolation, 268 
potentially regulated by IKZF3. Lenalidomide treatment for 72 hours also resulted in 269 
statistically significant increases in IFNg+ and TNFa+ frequencies, a decrease in IL-270 
17A+ frequencies, and a slight decrease in cell viability (median viability: 88.9%-271 
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82.75%, control vs lenalidomide respectively, Supplementary Figure 3B). Treatment 272 
of CD4+ T cells with lenalidomide also consistently increased secretion of IL-2 by 273 
CD4+ T cells after 3 days of anti-CD3/CD28 mAb stimulation (Supplemental Figure 274 
3C, n=5). 275 
 276 
IKZF3 is not sufficient to drive expression of IL10 in CD4+ T cells at the mRNA 277 
or protein level 278 
We next sought to determine whether IKZF3 was sufficient to drive IL-10 expression 279 
in CD4+ T cells. To overexpress IKZF3, we activated CD4+ T cells and transduced 280 
the cells with an IKZF3-IRES-GFP lentiviral construct (Lenti-IKZF3) or an empty vector 281 
(Lenti-EV) encoding only GFP (Figure 4A). After transduction, live GFP+ cells were 282 
sorted for mRNA isolation or rested and stimulated with PMA/ionomycin for 283 
intracellular cytokine staining. Whilst cells transduced with IKZF3 showed a significant 284 
increase in IKZF3 transcript, IL10 mRNA levels were low and not consistently 285 
increased by IKZF3 overexpression (Figure 4B). Also, at the protein level, IKZF3 286 
transduced cells did not show a consistent increase in IL-10 producing cells, compared 287 
to the empty vector (Figure 4C, D). A considerable proportion of cells was able to 288 
produce IFNγ or IL-17A indicating that the transduction protocol had not affected the 289 
capacity of the cells to produce cytokines. Together, these data indicate that IKZF3 290 
overexpression is not sufficient to drive IL-10 expression in CD4+ T cells. 291 
 292 
IKZF3 is insufficient to drive the expression of enhancer or promoter elements 293 
of IL10 294 
Our previous work showed that IKZF3 is able to bind evolutionary conserved regions 295 
at the IL10 locus in Th17 cells. To determine whether IKZF3 can drive transcription of 296 
IL10 via these regions, we identified 10 putative enhancer sites at the IL10 locus 297 
(Figure 5A), as defined by accessible chromatin (31), high H3K4me1 and low CpG 298 
methylation (from the BLUEPRINT consortium (32)). We cloned these regions and a 299 
1.5kb region of the IL10 promoter upstream of a Firefly luciferase open reading frame 300 
(pGL4). These vectors were then co-transfected with a control Renilla luciferase vector 301 
together with the plasmids: lenti-IKZF3 (Figure 5B) or lenti-MAF (Supplemental Figure 302 
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4B, C), a known regulator of IL10 (33). To validate that our constructs were functional, 303 
we stained HEK293T cells transfected with lenti-IKZF3, lenti-MAF or lenti-EV for IKZF3 304 
or cMAF by flow cytometry (Supplemental Figure 4A, B) and observed at least a 10-305 
fold increase in expression in the relevant conditions. 306 
The luciferase experiments showed that IKZF3 has limited capacity to drive 307 
transcription of the IL10 constructs (Figure 5B). An induction of reporter gene 308 
expression in response to IKZF3 transfection was only seen for enhancer 10, whilst 309 
reporter gene expression for most other constructs decreased in a dose-dependent 310 
manner upon increasing amounts of IKZF3. In contrast, transfection with cMAF, a 311 
known transcriptional regulator of IL10 (34, 35), significantly upregulated multiple 312 
enhancers compared to the empty vector (Supplemental Figure 4C).  313 
 314 
Discussion 315 
Regulation of IL-10 expression is a multi-layered process at the levels of 316 
transcription (33, 36), post-transcriptional stability (37, 38) and translation (39). In the 317 
innate immune system, IL-10 has been shown to be temporally regulated through 318 
regulation of transcript stability, such as through the p38/TTP axis (26, 37).  319 
We found that IL10 mRNA was maintained at higher levels in the presence of 320 
anti-TNFα mAb. This increase in IL-10+ producing CD4+ T cells does not appear to 321 
be attributable to changes in cell survival or increased cell proliferation after TNF 322 
blockade, as we showed recently (40). 323 
We also show that IL10 mRNA in anti-CD3/CD28-mAb activated primary human 324 
CD4+ T cells is an unstable transcript. This may represent a mechanism by which 325 
CD4+ T cells, which can transiently produce IL-10 on stimulation, eventually prevent 326 
its expression via negative feedback, similar to macrophages (41).  327 
In order to understand what drives the transcriptional regulation of IL10 we focussed 328 
on IKZF3. Our previous work with a CD4+ T cell:CD14+ monocyte co-culture system 329 
showed increased IKZF3 expression upon TNFα blockade in Th17 cells which 330 
correlated with increased IL-10 expression. In our current study using a T cell 331 
reductionist system, we saw no change in IKZF3 expression in cytokine producing 332 
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CD4+ T cell subsets upon TNFα blockade while still observing an increase in IL-333 
10+CD4+ T cell frequency. We did observe a generally higher level of IKZF3 334 
expression in IL-10 producing CD4+ T cells ex vivo and after CD3/CD28 stimulation. 335 
An association between IKZF3 and IL-10 producing CD4+ T cells has been noted by 336 
other studies in human Th17 clones (42), as well as mouse Th1 (5) and Th17 cells 337 
(8). This association may indicate common transcriptional regulators under steady-338 
state conditions, but not upon TNFα blockade. In our study, IKZF3 was highly 339 
expressed in IL-17A+IL-10+ CD4+ T cells. The expression of IKZF3 and IL-10 in 340 
“non-pathogenic” Th17 cells with a reduced capacity to drive experimental 341 
autoimmune encephalomyelitis, has been previously noted (6, 8). 342 
Similar to our findings with CD4+ T cells cultured without monocytes, another study 343 
found that memory CD4+ T cells activated by anti-CD3/CD28 mAb in the presence of 344 
the TNFα inhibitor drug etanercept, in the absence of monocytes, showed an 345 
increased expression of IL10 upon TNFα blockade which was not accompanied by 346 
changes in IKZF3 expression (43). 347 
IKZF3 (and IKZF1) has been previously described as a negative regulator of Il2 348 
expression in CD4+ T cells (6, 29), and our findings that IL-2 secretion is increased 349 
upon lenalidomide treatment support that observation. The expression of IL-10 and a 350 
reduced capacity to produce IL-2 is a known hallmark of Tregs. Therefore, high 351 
IKZF3 expression in the IL-10+ population might be indicative of a high proportion of 352 
Tregs. However, CyToF data from our lab did not reveal a higher expression of 353 
IKZF3 in CD25high CD127low Tregs compared to CD25low CD127high effector T cells ex 354 
vivo (data not shown). Furthermore, upon TNFα blockade we did not observe an 355 
increase in FOXP3+Tregs (10).  356 
Studies have implicated IL-2 signalling to be required for IL-10 expression by 357 
multiple Thelper subsets in vitro (44). Therefore, one could expect that blocking 358 
IKZF3, which is an IL2 transcriptional repressor would lead to an increase in IL-10 359 
production and frequency. However, we instead observed a significant reduction in 360 
the frequency of IL-10+CD4+ T cells in the presence of lenalidomide. 361 
From our data, lenalidomide also seems to have effects on the frequency of IL-17A, 362 
TNFα and IFNγ producing cells. The reduction in IL-17A+ CD4+ T cells could be due 363 
to the increase of IL-2 in the cell culture supernatants, which has been shown to 364 
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inhibit the differentiation of Th17 cells in humans (45, 46). Similarly, IL-2 has been 365 
shown to increase the expression of IFNγ in human CD4+ T cells (47, 48) and TNFα 366 
expression in mouse CD8+ T cells (49). It should be noted however, that expression 367 
of IFNγ and TNFα can be suppressed by IL-10 (50). Therefore, the decrease in IL-10 368 
expression accompanying lenalidomide treatment could boost the induction of IFNγ 369 
and TNFα producing cells. 370 
It should be considered that the effect of lenalidomide on IL-10 production in CD4+ T 371 
cells may be due to off target effects. Lenalidomide has been shown to downregulate 372 
several proteins including transcription factors (51-53). Therefore, the reduction in 373 
anti-CD3/CD28 mAb-induced IL-10 production, may stem from another lenalidomide 374 
sensitive protein, rather than IKZF3. IKZF1 has previously been shown to be affected 375 
by lenalidomide, and is capable of binding similar motifs to IKZF3. However, we 376 
previously observed no effect of anti-TNF on CD4+ T cell expression of IKZF1 (10) 377 
and do not see the same association of IKZF1 with IL-10 ex vivo. 378 
In order to determine whether IKZF3 expression was sufficient to drive IL-10 379 
expression, we overexpressed this protein in primary CD4+ T cells to determine its 380 
ability to drive IL10 mRNA and protein expression, as well as in the HEK293T cell 381 
line to determine if it could drive expression of putative IL10 enhancers or promoters. 382 
In both experimental approaches, we found that IKZF3 overexpression was not 383 
sufficient to drive the expression of IL-10. IKZF3 may require co-factors to promote 384 
transcription such as BLIMP1 (12) and STAT3 (13) which have been shown to 385 
interact with IKZF3. ENCODE data show that DNA binding motifs of these factors 386 
are in similar locations to IKZF family consensus motifs at the IL10 locus. It may be 387 
that these co-factors are not available in transduced CD4+ T cells or in HEK293T 388 
cells to facilitate IL10 mRNA or reporter expression. 389 
The effect of IKZF3 on most of the luciferase reporters is consistent with its reported 390 
function as a transcriptional repressor and indicates that IKZF3 is unable to directly 391 
drive IL10 expression, even when enhancers and promoters are accessible to bind 392 
(6, 15). These reporters were based on ATAC-seq data (31) which should be 393 
reflective of the accessible regions in CD4+ T cells ex vivo. Changes to chromatin by 394 
anti-CD3/CD28 mAb stimulation, however, could reveal other enhancers which 395 
IKZF3 can bind to drive expression. 396 
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It should be noted that IKZF3 has a number of splice variants which have varying 397 
abilities to drive gene expression (15).  Our data suggest that CD4+ T cells 398 
predominantly express the largest isoform of ~70 kDa, and this is the isoform we 399 
cloned in our overexpression studies. This isoform has previously been shown to 400 
drive gene expression in mouse TFH-like cells and it is therefore possible that this 401 
isoform could drive transcription in human CD4+ T cells (13). However, we cannot 402 
rule out that other IKZF3 isoforms may differentially affect IL10 expression.  403 
In summary, this study shows that IKZF3 expression is associated with IL-10+CD4+ 404 
T cells at the protein level, and that pharmacological inhibition of IKZF3 disrupts the 405 
ability of CD4+ T cells to produce IL-10. However, the expression of IKZF3 is not 406 
sufficient to drive IL-10 protein or mRNA expression. We also note that while TNFα 407 
blockade does lead to increased IL10 mRNA expression this is not necessarily 408 
attributable to differential expression of IKZF3. Further work is required to establish 409 
the transcription factors modified by TNFα blockade which lead to increased IL10 410 
expression, and whether such transcriptional regulation occurs in patients treated 411 
with TNFα inhibitors.  412 
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Figure 1. TNFα blockade maintains the expression of IL-10 in CD4+ T cells 634 
which involves active transcription.(A, B) Primary CD4+ T cells from healthy 635 
donors were stimulated with anti-CD3/CD28 mAb for 0, 1, 2 or 3 days in the absence 636 
(blue bars) or presence (red bars) of 1 μg/mL adalimumab.  Cells were restimulated 637 
with PMA and ionomycin and assessed for IL-10 expression. Representative (A) and 638 
cumulative (B, n=7) data showing the frequency of IL-10 expressing cells within 639 
CD4+ T cells. (C) IL10 mRNA expression was analysed by qPCR after 1, 2 or 3 days 640 
in culture without restimulation (n=6). Data in B, C analysed by 2-Way ANOVA. (D) 641 
Quantification of IL-10 in cell culture supernatants from CD4+ T cells stimulated as 642 
above for three days (n=7, Wilcoxon test). (E) After 3 days of culture as above, 643 
CD4+ T cells were treated with either DMSO or 1μg/mL Actinomycin D for 120 644 
minutes to block transcription. mRNA abundance was assessed by qPCR (n=5, 2-645 
way ANOVA with multiple comparisons, comparing DMSO and actinomycin D 646 
treatment conditions within each group, as well as actinomycin D treated cells 647 
between cells stimulated in the absence or presence of 1 μg/mL adalimumab). 648 
 649 
Figure 2. IKZF3 is associated with IL-10 producing CD4+ T cells. (A, B) Primary 650 
CD4+ T cells from healthy donors were stimulated with PMA and ionomycin, and 651 
assessed for frequency of cytokine producing cells and IKZF3 expression. 652 
Representative (A) and cumulative data shown (B, n=8). (C-F) CD4+ T cells were 653 
stimulated with anti-CD3/CD28 mAb for 3 days and subsequently restimulated with 654 
PMA and ionomycin, and assessed for frequency of cytokine producing cells and 655 
IKZF3 expression. Expression of IKZF3 was calculated within total populations of 656 
cytokine producing cells (C, D) or within- IL-10+ or IL10- subsets, within those 657 
populations (E, F). Representative (C) and cumulative (D, n=13) data of total 658 
cytokine producing populations are shown. Representative (E) and cumulative (F, 659 
n=8-11) data for IKZF3 expression within IL-10+ and IL-10- subsets are shown. Data 660 
in B and D, analysed by ANOVA, data in F analysed by Wilcoxon test.  661 
 662 
Figure 3. Lenalidomide disrupts the anti-CD3/CD28 mAb mediated induction of 663 
IL-10+ CD4+ T cells but does not affect ex vivo IL-10 production. (A, B) Primary 664 
 22 
CD4+ T cells from healthy donors were treated with 0.1, 1 or, 10 µM of lenalidomide 665 
overnight and examined for IKZF3 expression by Western blot (A) or flow cytometry 666 
(B). (C) CD4+ T cells were treated with 1 µM lenalidomide overnight and then 667 
stimulated with PMA and ionomycin and assessed for IKZF3 expression and 668 
frequency of IL-10+ CD4+ T cells (n= 13). (D) CD4+ T cells were stimulated with 669 
anti-CD3/CD28 mAb for 3 days in the presence of 1 µM lenalidomide and 670 
subsequently restimulated with PMA and ionomycin and assessed for IKZF3 671 
expression and frequency of IL-10+CD4+ T cells (n=13). Data in C and D analysed 672 
by Wilcoxon test. 673 
 674 
Figure 4. IKZF3 overexpression in CD4+ T cells is not sufficient to drive the 675 
expression of IL10. (A-D) Primary CD4+ T cells from healthy donors were 676 
transduced with an IKZF3-IRES-GFP (Lenti-IKZF3) or GFP only (Lenti-EV) lentivirus. 677 
7 days post transduction cells were sorted on GFP expression. (A) Representative 678 
GFP expression. (B) CD4+ T cells transduced with lenti-IKZF3 or Lenti-EV were 679 
sorted on GFP expression and mRNA expression of IKZF3 and IL10 was quantified 680 
by qPCR (n=6). (C, D) Cells transduced with Lenti-IKZF3 or Lenti-EV were sorted on 681 
GFP expression, rested overnight, then restimulated with PMA and ionomycin and 682 
assessed for frequency of IL-10, IFNγ or IL-17A producing cells. Representative (C) 683 
and cumulative (D, n=6-8) data shown. Data in B and D analysed by Wilcoxon test. 684 
 685 
Figure 5. IKZF3 is insufficient to drive transcriptional activity via the IL10 686 
promoter or local enhancers. (A) ChIP-seq (from the Blueprint consortium) and 687 
ATAC-seq data (from Buenrostro et al. 2015) from ex vivo human CD4+ T cells for 688 
the MAPKAPK2:IL10:IL19 locus was used to identify regions of putative enhancers 689 
(yellow vertical bars, numbered 1-10) as well as 1.5kb promoter region of IL10 690 
(vertical green bar, labelled Promo). (B) These promoter and enhancer regions were 691 
then cloned upstream of a luciferase reading frame and transfected along with an 692 
expression plasmid encoding IKZF3 (Lenti-IKZF3) or empty vector control (Lenti-EV) 693 
into HEK293T cells and assessed 48 hours later for luciferase activity (n=4). Data 694 
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Supplemental Figure 1. Gating strategy for flow cytometry data. (A, B) CD4+ T cells were isolated from the 
peripheral blood of healthy donors and gated on live (A) CD3+ events or (B) CD3+ CD4+. This gating strategy 
was used in Figures 1A and B, 2A-F, 3B-D, Supplemental Figure 2B, Supplemental Figure 3A and B. (C) CD4+ T 
cells were isolated from the peripheral blood of healthy donors and cultured at a 1:1 ratio with autologous 
CD14+ monocytes and gated on Live CD14- CD3+ Events. This gating strategy was used in Supplemental 
Figure 2A. (D) CD4+ T cells were stimulated and transduced with lentiviral particles for 7 days and then 
sorted on Live GFP+ CD3+ events by a FACS ARIA. The depicted gating strategy was used in the analysis of 
Figure 4C and D. (E) HEK293T cells were transfected with plasmids encoding IKZF3 or cMAF as well as GFP. 
These cells were subsequently stained for viability, IKZF3 and cMAF and gated on Live cell events. This gating 
strategy was used in Supplemental Figure 4A and B.
 29 
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CD4+ T cell: Monocyte Coculture
CD4+T cell only
Supplemental Figure 2. TNF blockade does not alter IKZF3 expression in CD4+ T cells in the absence of 
monocytes. (A) CD4+ T cells and CD14+ monocytes from healthy donors were cultured together at a 1:1 
ratio for 3 days with anti-CD3 mAb in the absence (blue circles) or presence (red circles) of 1 µg/mL 
adalimumab. Cells were restimulated with PMA and ionomycin and assessed for cytokine and IKZF3 
expression (n=13). (B) Primary CD4+ T cells were stimulated with anti-CD3/CD28 mAb for 3 days in the 
absence or presence of 1µg/mL adalimumab. Cells were restimulated with PMA and ionomycin and assessed 
for cytokine and IKZF3 expression (n= 9). (C) Primary CD4+ T cells were stimulated with anti-CD3/CD28 mAb
for 0, 1 or 3 days in the absence or presence of 1µg/mL adalimumab and assessed for IKZF3 expression 






































































































































































3 days anti-CD3/CD28 stimulation
A
B
Supplemental Figure 3. The effect of lenalidomide on CD4+ T cell cytokine production and viability. 
(A) CD4+ T cells were treated with 1 µM lenalidomide overnight and then stimulated with PMA and 
ionomycin and assessed for frequencies of IFNy+, IL-17A+ and live CD4+ T cells (n=10-11). (B and C) 
CD4+ T cells were stimulated with anti-CD3/CD28 mAb for 3 days in the presence of 1 µM lenalidomide 
or DMSO control and (B) subsequently restimulated with PMA and ionomycin and assessed for IFNy+, 
IL-17A+, TNF+ and live CD4+ T cells (by staining with Live/Dead discriminator dye). (C) Cell culture 
supernatants of CD4+ T cells treated with DMSO or lenalidomide were assessed for IL-2 secretion 


















































































































Supplemental Figure 4. Overexpression of proteins in HEK293T cells. (A,B) HEK293T cells were 
transfected with 2 μg of Lenti-IKZF3, Lenti-EV or Lenti-MAF for 48 hours and assessed for IKZF3 or 
cMAF expression by flow cytometry. (A) Representative histograms and (B) cumulative data (n=4) are 
shown. (C) HEK293T cells were transfected with the putative IL10 enhancer and promoter reporter 
plasmids in addition to Lenti-EV or Lenti-MAF (n=4). Data in C analysed by 2-way ANOVA with multiple 
comparisons.
